

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
January 9, 2023

DRAFT QUESTIONS

1. **DISCUSSION:** Discuss how the studied use of aflibercept in the treatment of retinopathy of prematurity can best be communicated to physicians and the caregivers of these premature infants.

2. **DISCUSSION:** Discuss potential labeling including:
 - a. Wording of Indications and Usage
 - b. Wording of Warnings/Precautions
 - c. Wording of Dosing and Administration
 - d. Wording of Pediatric Use
 - e. Wording of the Clinical Trials section

DRAFT